ALVR – AlloVir, Inc.
AlloVir, Inc.ALVR
$9.28Name : AlloVir, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $46,628,752.00
EPSttm : -20.24
AlloVir, Inc.
$9.28
3.11%$0.28Float Short %
2.43
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.01
EPS Last/This Y
41.67
EPS This/Next Y
0.1
Price
9.43
Target Price
20.7
Analyst Recom
4
Performance Q
-49.6
Relative Volume
4.46
Beta
0.64
Ticker: ALVR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | ALVR | 0.4622 | N/A | N/A | 0 |
| 2024-12-20 | ALVR | 0.4218 | N/A | N/A | 0 |
| 2024-12-23 | ALVR | 0.4584 | N/A | N/A | 0 |
| 2024-12-24 | ALVR | 0.4742 | N/A | N/A | 0 |
| 2024-12-26 | ALVR | 0.4735 | 0.10 | 0.00 | 299 |
| 2024-12-27 | ALVR | 0.445 | 0.10 | 0.00 | 299 |
| 2024-12-30 | ALVR | 0.4477 | 0.10 | 0.00 | 299 |
| 2024-12-31 | ALVR | 0.421 | 0.10 | 0.00 | 299 |
| 2025-01-02 | ALVR | 0.45 | 0.10 | 0.00 | 299 |
| 2025-01-03 | ALVR | 0.443 | N/A | N/A | 0 |
| 2025-01-06 | ALVR | 0.4729 | 0.00 | 0.00 | 682 |
| 2025-01-07 | ALVR | 0.4701 | 0.00 | 0.00 | 687 |
| 2025-01-08 | ALVR | 0.445 | 0.00 | 0.00 | 687 |
| 2025-01-09 | ALVR | 0.4498 | 0.00 | 0.00 | 687 |
| 2025-01-10 | ALVR | 0.433 | 0.00 | 0.00 | 687 |
| 2025-01-13 | ALVR | 0.402 | 0.00 | 0.00 | 687 |
| 2025-01-14 | ALVR | 0.3975 | 0.00 | 0.00 | 687 |
| 2025-01-15 | ALVR | 0.3872 | N/A | N/A | 0 |
| 2025-01-16 | ALVR | 9 | N/A | N/A | 0 |
| 2025-01-17 | ALVR | 9.425 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | ALVR | 0.45 | - | - | -0.42 |
| 2024-12-20 | ALVR | 0.42 | - | - | -0.42 |
| 2024-12-23 | ALVR | 0.45 | - | - | -0.42 |
| 2024-12-24 | ALVR | 0.47 | - | - | -0.42 |
| 2024-12-26 | ALVR | 0.47 | - | - | -0.42 |
| 2024-12-27 | ALVR | 0.46 | - | - | -0.42 |
| 2024-12-30 | ALVR | 0.45 | - | - | -0.42 |
| 2024-12-31 | ALVR | 0.43 | - | - | -0.42 |
| 2025-01-02 | ALVR | 0.45 | - | - | -0.42 |
| 2025-01-03 | ALVR | 0.45 | - | - | -0.42 |
| 2025-01-06 | ALVR | 0.47 | - | - | -0.42 |
| 2025-01-07 | ALVR | 0.47 | - | - | -0.42 |
| 2025-01-08 | ALVR | 0.45 | - | - | -0.42 |
| 2025-01-09 | ALVR | 0.45 | - | - | -0.42 |
| 2025-01-10 | ALVR | 0.44 | - | - | -0.42 |
| 2025-01-13 | ALVR | 0.41 | - | - | -0.42 |
| 2025-01-14 | ALVR | 0.40 | - | - | -0.42 |
| 2025-01-15 | ALVR | 0.39 | - | - | -0.42 |
| 2025-01-16 | ALVR | 9.00 | - | - | -0.42 |
| 2025-01-17 | ALVR | 9.43 | - | - | -0.42 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | ALVR | -0.16 | -9.31 | 3.72 |
| 2024-12-20 | ALVR | -0.16 | -9.31 | 3.72 |
| 2024-12-23 | ALVR | -0.18 | -9.31 | 3.72 |
| 2024-12-24 | ALVR | -0.18 | -9.31 | 3.72 |
| 2024-12-26 | ALVR | -0.15 | -9.31 | 3.27 |
| 2024-12-27 | ALVR | -0.16 | -9.31 | 3.27 |
| 2024-12-30 | ALVR | -0.17 | -9.37 | 3.27 |
| 2024-12-31 | ALVR | -0.17 | -9.37 | 3.27 |
| 2025-01-02 | ALVR | -0.17 | -9.37 | 3.27 |
| 2025-01-03 | ALVR | -0.16 | -9.37 | 3.27 |
| 2025-01-06 | ALVR | -0.16 | -10.27 | 3.27 |
| 2025-01-07 | ALVR | -0.16 | -10.27 | 3.27 |
| 2025-01-08 | ALVR | -0.16 | -10.27 | 3.27 |
| 2025-01-09 | ALVR | -0.16 | -10.27 | 3.27 |
| 2025-01-10 | ALVR | -0.16 | -10.27 | 3.27 |
| 2025-01-13 | ALVR | -0.16 | -10.27 | 2.43 |
| 2025-01-14 | ALVR | -0.16 | -10.27 | 2.43 |
| 2025-01-15 | ALVR | -0.16 | -10.27 | 2.43 |
| 2025-01-16 | ALVR | -0.16 | -10.27 | 2.43 |
| 2025-01-17 | ALVR | -3.58 | -10.27 | 2.43 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.09
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
-3.58
Institutional Transactions
-10.27
Beta
0.64
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
8
Growth Score
20
Sentiment Score
5
Actual DrawDown %
94.3
Max Drawdown 5-Year %
Target Price
20.7
P/E
Forward P/E
PEG
P/S
P/B
0.38
P/Free Cash Flow
EPS
-20.16
Average EPS Est. Cur. Y
-0.42
EPS Next Y. (Est.)
-0.32
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
4.46
Return on Equity vs Sector %
-101.8
Return on Equity vs Industry %
-89.2
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.12
EBIT Estimation
AlloVir, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 8
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
stock quote shares ALVR – AlloVir, Inc. Stock Price stock today
news today ALVR – AlloVir, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALVR – AlloVir, Inc. yahoo finance google finance
stock history ALVR – AlloVir, Inc. invest stock market
stock prices ALVR premarket after hours
ticker ALVR fair value insiders trading